Kempharm Stock Fundamentals

KMPHDelisted Stock  USD 5.81  0.02  0.34%   
KemPharm fundamentals help investors to digest information that contributes to KemPharm's financial success or failures. It also enables traders to predict the movement of KemPharm Stock. The fundamental analysis module provides a way to measure KemPharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to KemPharm stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

KemPharm Total Asset Analysis

KemPharm's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Total Asset

 = 

Tangible Assets

+

Intangible Assets

More About Total Asset | All Equity Analysis

Current KemPharm Total Asset

    
  132.94 M  
Most of KemPharm's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, KemPharm is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
Competition

Based on the latest financial disclosure, KemPharm has a Total Asset of 132.94 M. This is 98.23% lower than that of the Pharmaceuticals sector and 93.27% lower than that of the Health Care industry. The total asset for all United States stocks is 99.55% higher than that of the company.

KemPharm Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining KemPharm's current stock value. Our valuation model uses many indicators to compare KemPharm value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across KemPharm competition to find correlations between indicators driving KemPharm's intrinsic value. More Info.
KemPharm is currently regarded as number one stock in cash and equivalents category among related companies. It is currently regarded as number one stock in operating margin category among related companies . . Comparative valuation analysis is a catch-all model that can be used if you cannot value KemPharm by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for KemPharm's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the KemPharm's earnings, one of the primary drivers of an investment's value.

KemPharm Short Ratio Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses KemPharm's direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of KemPharm could also be used in its relative valuation, which is a method of valuing KemPharm by comparing valuation metrics of similar companies.
KemPharm is currently under evaluation in short ratio category among related companies.

KemPharm Fundamentals

About KemPharm Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze KemPharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of KemPharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of KemPharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Kempharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 24 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards KemPharm in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, KemPharm's short interest history, or implied volatility extrapolated from KemPharm options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Other Consideration for investing in KemPharm Stock

If you are still planning to invest in KemPharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the KemPharm's history and understand the potential risks before investing.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
AI Investment Finder
Use AI to screen and filter profitable investment opportunities